CoreMedic’s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart. ChordArt™ offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access.
ChordArt is designed to allow mitral repair in a wider patient population. ChordArt™ is currently under clinical evaluation in European clinics.
CoreMedic is a privately held medical device company headquartered in Radolfzell, Germany with a subsidiary in Biel/Bienne, Switzerland. CoreMedic is EN ISO 13485 certified.
For further information, please visit www.coremedic.ch
Overview
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 29, 2023 | Swiss medtech startups enter next development phase |
Reviews 0
FAQ about CoreMedic
When was CoreMedic founded?
CoreMedic was founded in 2012.
What has the press written about CoreMedic?
Parsers VC has collected 2 articles mentioning CoreMedic, among them “Swiss medtech startups enter next development phase” (Nov 29, 2023).
Is CoreMedic still active?
Yes, CoreMedic is active; its latest activity on Parsers VC dates from Jan 3, 2024.